These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31691817)

  • 1. Aminoglycoside versus carbapenem or piperacillin/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae.
    Zohar I; Schwartz O; Yossepowitch O; David SSB; Maor Y
    J Antimicrob Chemother; 2020 Feb; 75(2):458-465. PubMed ID: 31691817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of elderly patients with bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae in an Italian Internal Medicine ward.
    Meini S; Laureano R; Tascini C; Arena F; Fani L; Frullini A; Passaleva MT; Roberts AT; Mannini D; Sbrana F; Ripoli A; Rossolini GM
    Eur J Intern Med; 2018 Feb; 48():50-56. PubMed ID: 29089174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis.
    Hoashi K; Hayama B; Suzuki M; Sakurai A; Takehana K; Enokida T; Takeda K; Ohkushi D; Doi Y; Harada S
    Microbiol Spectr; 2022 Aug; 10(4):e0220622. PubMed ID: 35916524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
    Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
    Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
    Huang SS; Lee MH; Leu HS
    J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ng TM; Khong WX; Harris PN; De PP; Chow A; Tambyah PA; Lye DC
    PLoS One; 2016; 11(4):e0153696. PubMed ID: 27104951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ofer-Friedman H; Shefler C; Sharma S; Tirosh A; Tal-Jasper R; Kandipalli D; Sharma S; Bathina P; Kaplansky T; Maskit M; Azouri T; Lazarovitch T; Zaidenstein R; Kaye KS; Marchaim D
    Infect Control Hosp Epidemiol; 2015 Aug; 36(8):981-5. PubMed ID: 25990361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems.
    Tan SH; Ng TM; Chew KL; Yong J; Wu JE; Yap MY; Heng ST; Ng WHW; Wan S; Cheok SJH; Tambyah PA; Lye DC
    Int J Antimicrob Agents; 2020 Feb; 55(2):105860. PubMed ID: 31841674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia.
    Khoo AL; Zhao YJ; Teng M; Ying D; Jin J; Chee YL; Poon LM; Lim SE; Koh LP; Chng WJ; Lim BP; Hsu LY; Chai LYA
    Int J Antimicrob Agents; 2018 Sep; 52(3):350-357. PubMed ID: 29751120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of piperacillin-tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing
    Zhang W; Yan CY; Li SR; Fan TT; Cao SS; Cui B; Li MY; Fan BY; Ji B; Wang L; Cui F; Cui J; Wang L; Guan Y; Wang JW
    Front Cell Infect Microbiol; 2023; 13():1093842. PubMed ID: 37207190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing
    Benanti GE; Brown ART; Shigle TL; Tarrand JJ; Bhatti MM; McDaneld PM; Shelburne SA; Aitken SL
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Han SB; Lee SC; Lee SY; Jeong DC; Kang JH
    BMC Infect Dis; 2015 Oct; 15():414. PubMed ID: 26464143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
    Sfeir MM; Askin G; Christos P
    Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-carbapenem therapy of urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae.
    de La Blanchardière A; Dargère S; Guérin F; Daurel C; Saint-Lorant G; Verdon R; Cattoir V
    Med Mal Infect; 2015 May; 45(5):169-72. PubMed ID: 25845927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-spectrum β-lactamase-producing Enterobacteriaceae, national study of antimicrobial treatment for pediatric urinary tract infection.
    Lagree M; Bontemps S; Dessein R; Angoulvant F; Madhi F; Martinot A; Cohen R; Dubos F;
    Med Mal Infect; 2018 May; 48(3):193-201. PubMed ID: 29449049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study.
    Meije Y; Pigrau C; Fernández-Hidalgo N; Clemente M; Ortega L; Sanz X; Loureiro-Amigo J; Sierra M; Ayestarán A; Morales-Cartagena A; Ribera A; Duarte A; Abelenda G; Rodríguez-Baño J; Martínez-Montauti J
    Int J Antimicrob Agents; 2019 Aug; 54(2):189-196. PubMed ID: 31075401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae.
    Su J; Guo Q; Li Y; Wu S; Hu F; Xu S; Wang M
    J Antimicrob Chemother; 2018 Nov; 73(11):3176-3180. PubMed ID: 30099554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Carbapenem Therapy Necessary for the Treatment of Non-CTX-M Extended-Spectrum β-Lactamase-Producing Enterobacterales Bloodstream Infections?
    Hareza DA; Cosgrove SE; Simner PJ; Harris AD; Bergman Y; Conzemius R; Jacobs E; Beisken S; Tamma PD
    Clin Infect Dis; 2024 May; 78(5):1103-1110. PubMed ID: 37972276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
    Park SH; Choi SM; Chang YK; Lee DG; Cho SY; Lee HJ; Choi JH; Yoo JH
    J Antimicrob Chemother; 2014 Oct; 69(10):2848-56. PubMed ID: 24928854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.